Principal Investigators

    JANSSEN PHARMACEUTICA

    Institution

    JANSSEN PHARMACEUTICA

    Contact information of lead PI

    Country

    Belgium

    Title of project or programme

    Biomarker based adaptive development in Alzheimer disease (BioAdaptAD)

    Source of funding information

    Flanders Innovation & Entrepreneurship

    Total sum awarded (Euro)

    € 2,241,280

    Start date of award

    01/06/2013

    Total duration of award in years

    4.0

    The project/programme is most relevant to:

    Alzheimer's disease & other dementias

    Keywords

    Research Abstract

    The general objectives of this project are to develop a BACE inhibitor for disease modification in Alzheimer’s disease and to explore the development in an earlier prodromal Alzheimer’s disease population. From a drug development perspective, this will involve multiple adaptation steps and the intensive use of biomarkers.

    Lay Summary

    Further information available at:

Types: Investments > €500k
Member States: Belgium
Diseases: Alzheimer's disease & other dementias
Years: 2016
Database Categories: N/A
Database Tags: N/A

Export as PDF